Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-67908-4
Abstract: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) have shown promise against non-small cell lung cancers (NSCLCs) in clinics but the utility is often short-lived because of T790M mutations in EGFR that help evade TKIs’… read more here.
Keywords: t790m mutations; pre let; wnt1 tcf; osimertinib resistance ... See more keywords
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling
Sign Up to like & getrecommendations! Published in 2022 at "Communications Biology"
DOI: 10.1038/s42003-022-03111-7
Abstract: Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. Interleukin-6 (IL-6) is a… read more here.
Keywords: fak signaling; resistance; laminin fak; osimertinib resistance ... See more keywords
Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz238.034
Abstract: Abstract Background The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib improves therapy for non-small cell lung cancer (NSCLC) patients who possess EGR mutations. However, invariable acquired resistance appears due to several molecular mechanisms.… read more here.
Keywords: hsp90 inhibitors; osimertinib resistance; oncology; non small ... See more keywords
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14929
Abstract: BACKGROUND Osimertinib is the first-line treatment for patients with epidermal growth factor receptor (EGFR) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR is in an immunosuppressive tumor… read more here.
Keywords: time; tumor immune; osimertinib resistance; resistance ... See more keywords
Hsa_circ_0005576 promotes the osimertinib resistance through miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer science"
DOI: 10.1111/cas.15177
Abstract: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung adenocarcinoma (LUAD) harboring activating mutations, but patients ultimately develop acquired resistance. Circular RNAs are involved in EGFR-TKI resistance, while the role… read more here.
Keywords: luad; mir 512; osimertinib resistance; hsa circ ... See more keywords
Abstract 1752: Darolutamide reverses osimertinib resistance in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1752
Abstract: Targeted therapies, such as EGFR inhibitors, have improved survival for patients with non-small cell lung cancer (NSCLC). Overall cure rates remain low due to eventual development of resistance. Osimertinib is a third-generation EGFR inhibitor that… read more here.
Keywords: cell; non small; combination; osimertinib resistance ... See more keywords
N6-Methyladenosine Modification of CIRCKRT17 Initiated by METTL3 Promotes Osimertinib Resistance of Lung Adenocarcinoma by EIF4A3 to Enhance YAP1 Stability
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14225582
Abstract: Simple Summary Circular RNA KRT17 (circKRT17) is elevated in osimertinib-resistant lung cancer cells by a circRNA microarray analysis. However, the functional role of circKRT17 in the osimertinib resistance of lung adenocarcinoma (LUAD) remains undetermined. Herein,… read more here.
Keywords: modification; circkrt17; luad; osimertinib resistance ... See more keywords
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15082263
Abstract: Simple Summary Potential application of CDK12/13 inhibitor in overcoming resistance to osimertinib, a third-generation EGFR TKI, in vitro and in vivo. Abstract Osimertinib is a third-generation epidermal growth factor receptor and tyrosine kinase inhibitor (EGFR-TKI)… read more here.
Keywords: egfr mutant; osimertinib resistance; resistance; lung adenocarcinoma ... See more keywords
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms231810415
Abstract: Background: Osimertinib-based therapy effectively improves the prognosis of lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However, patients will have cancer progression after approximately one year due to the occurrence of drug resistance.… read more here.
Keywords: osimertinib resistance; resistance; polarization; macrophage ... See more keywords
Hsa_circ_0007312 Promotes Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance through Pyroptosis and Apoptosis via the MiR-764/MAPK1 Axis in Lung Adenocarcinoma Cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer"
DOI: 10.7150/jca.72066
Abstract: Purposes: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used for patients with gefitinib (first-generation EGFR-TKI) resistance, but osimertinib resistance inevitably occurs. Therefore, it is necessary to explore the mechanisms of osimertinib… read more here.
Keywords: 764 mapk1; circ7312; osimertinib resistance; resistance ... See more keywords